Thrombosis in patients with hereditary fibrinogen deficiency

Introduction. In most cases, in patients with hereditary fibrinogen deficiency, clinical manifestations are represented by bleeding of varying intensity and localization. However, the clinical picture of hereditary fibrinogen deficiency can also be represented by thrombosis.

Aim — to characterize the detected mutations in fibrinogen genes and to analyze prothrombotic factors in patients with hereditary hypofibrinogenemia and thrombosis.

Materials and methods. Forty-nine patients with hereditary hypofibrinogenemia were observed, of which 46 patients had no history of thrombosis and 3 patients had a confirmed history of thrombosis. These 3 patients made up the study group.

Results. Heterozygous mutations were found in all 3 patients in the fibrinogen gamma chain gene (FGG), one of them had a previously undescribed deletion g.2653_2684+211del, p.(Asp167Glufs*2), which removes 32 terminal nucleotides of the fifth exon of the FGG gene and leads to the formation of a stop codon in place of amino acid 168. In two other patients, there were missense mutations c.1140T>A, p.(Cys365Ser) and c.1114A>T, p.(Asp356Val), which can determine the thrombogenic properties of the altered protein structure of fibrinogen. Other prothrombotic factors were also identified: genetic polymorphisms of low thrombotic risk, surgery, taking combined oral contraceptives.

Conclusion. Hereditary fibrinogen deficiency does not play a protective role in relation to the development of thrombosis and may cause the development of thrombosis, which is associated with its multifunctional role in the hemostasis system. The pathogenesis of thrombosis in patients with hereditary hypofibrinogenemia is multifactorial and may be associated with the characteristics of the main protein defect and the coexistence of hereditary and acquired thrombotic risk factors (surgical interventions, taking combined oral contraceptives, etc.).

1. Franchini M., Marano G., Pupella S., et al. Rare congenital bleeding disorders. Ann Transl Med. 2018; 6(17): 331. DOI: 10.21037/atm.2018.08.34.

2. Palla R., Peyvandi F., Shapiro AD. Rare bleeding disorders: Diagnosis and treatment. Blood. 2015; 125(13): 2052–61. DOI: 10.1182/blood-2014-08-532820.

3. Mumford A.D., Ackroyd S., Alikhan R., et al. Guideline for the diagnosis and management of the rare coagulation disorders: United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2014; 167(3): 304–26. DOI: 10.1111/bjh.13058.

4. Acharya S.S., Dimichele D.M. Rare inherited disorders of fibrinogen. Haemophilia. 2008; 14(6): 1151–8. DOI: 10.1111/j.1365-2516.2008.01831.x.

5. Shetty S., Shelar T., Mirgal D., et al. Rare coagulation factor deficiencies: A countrywide screening data from India. Haemophilia. 2014; 20(4): 575–81. DOI: 10.1111/hae.12368.

6. Neerman-Arbez M., Casini A. Clinical consequences and molecular bases of low fibrinogen levels. Int J Mol Sci. 2018; 19(1): 192. DOI: 10.3390/ijms19010192.

7. Ruiz-Sáez A. Thrombosis in rare bleeding disorders. Hematology. 2012; 17(Suppl 1): S156–8. DOI: 10.1179/102453312X13336169156690.

8. Yakovleva E.V., Surin V.L., Selivanova D.S., et al. Hereditary afibrinogenemia: A literature review and clinical observations. Terapevticheskiy arkhiv. 2016; 88(12): 120–5. DOI: 10.17116/terarkh20168812120-125. (In Russian).

9. Mosesson M.W. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005; 3(8): 1894–904. DOI: 10.1111/j.1538-7836.2005.01365.x.

10. Weisel J.W., Litvinov R.I. Fibrin formation, structure and properties. Subcell Biochem. 2017; 82: 405–56. DOI: 10.1007/978-3-319-49674-0_13.

11. Vilar R., Fish R.J., Casini A, Neerman-Arbez M. Fibrin(ogen) in human disease: Both friend and foe. Haematologica. 2020; 105(2): 284–96. DOI: 10.3324/haematol.2019.236901.

12. Ariëns R.A. Fibrin(ogen) and thrombotic disease. J Thromb Haemost. 2013; 11(Suppl 1): 294–305. DOI: 10.1111/jth.12229.

13. Mosesson M.W. Update on antithrombin I (fibrin). Thromb Haemost. 2007; 98(1): 105–8.

14. Mosesson M.W. Antithrombin I. Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost. 2003; 89(1): 9–12.

15. Simurda T., Brunclikova M., Asselta R., et al. Genetic variants in the FGB and FGG genes mapping in the beta and gamma nodules of the fibrinogen molecule in congenital quantitative fibrinogen disorders associated with a thrombotic phenotype. Int J Mol Sci. 2020; 21(13): 4616. DOI: 10.3390/ijms21134616.

16. Gallastegui N., Kimble E.L., Harrington T.J. Resolution of fibrinogen deficiency in a patient with congenital afibrinogenemia after liver transplantation. Haemophilia. 2016; 22(1): e48–51. DOI: 10.1111/hae.12802.

17. Takasugi Y., Shiokawa Y., Kajikawa R., et al. Mesenteric venous thrombosis in a patient with congenital afibrinogenemia and diffuse peritonitis. Ann Hematol. 2005; 84(2): 129–30. DOI: 10.1007/s00277-004-0958-4.

18. Sartori M.T., Milan M., de Bon E., et al. Thrombosis of abdominal aorta in congenital afibrinogenemia: Case report and review of literature. Haemophilia. 2015; 21(1): 88–94. DOI: 10.1111/hae.12507.

19. Simsek I., de Mazancourt P., Horellou M.H., et al. Afibrinogenemia resulting from homozygous nonsense mutation in A alpha chain gene associated with multiple thrombotic episodes. Blood Coagul Fibrinolysis. 2008; 19(3): 247–53. DOI: 10.1097/MBC.0b013e3282f564fd.

20. Dupuy E., Soria C., Molho P., et al. Embolized ischemic lesions of toes in an afibrinogenemic patient: Possible relevance to in vivo circulating thrombin. Thromb Res. 2001; 102(3): 211–9. DOI: 10.1016/s0049-3848(01)00247-x.

21. De Moerloose P., Boehlen F., Neerman-Arbez M. Fibrinogen and the risk of thrombosis. Semin Thromb Hemost. 2010; 36(1): 7–17. DOI: 10.1055/s-0030-1248720.

22. Fuchs R.J., Levin J., Tadel M., Merritt W. Perioperative coagulation management in a patient with afibrinogenemia undergoing liver transplantation. Liver Transpl. 2007; 13(5): 752–6. DOI: 10.1002/lt.21164.

23. Ozdemir M.A., Işik B., Patiroglu T., et al. A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations. Blood Coagul Fibrinolysis. 2015; 26(3): 354–6. DOI: 10.1097/MBC.0000000000000200.

24. Ruiz-Saez A. Occurrence of thrombosis in rare bleeding disorders. Semin Thromb Hemost. 2013; 39(6): 684–92. DOI: 10.1055/s-0033-1353391.

25. Acharya S.S., Dimichele D.M. Rare inherited disorders of fibrinogen. Haemophilia. 2008; 14(6): 1151–8. DOI: 10.1111/j.1365-2516.2008.01831.x.

26. Casini A., Undas A., Palla R., et al. Subcommittee on factor XIII and fibrinogen. Diagnosis and classification of congenital fibrinogen disorders: Communication from the SSC of the ISTH. J Thromb Haemost. 2018; 16(9): 1887–90. DOI: 10.1111/jth.14216.

27. HGMD. URL: http://www.hgmd.cf.ac.uk/ac/index.php

28. Brennan S.O., Laurie A., Smith M. Novel FGG variant (γ339C→S) confirms importance of the γ326-339 disulphide bond for plasma expression of newly synthesised fibrinogen. Thromb Haemost. 2015; 113(4): 903–5. DOI: 10.1160/TH14-10-0849.

29. Zhang J.Z., Redman C. Fibrinogen assembly and secretion. Role of intrachain disulfide loops. J Biol Chem. 1996; 271(47): 30083–8. DOI: 10.1074/jbc.271.47.30083.

30. Chinni E., Tiscia G., Favuzzi G., et al. Identification of novel mutations in patients with fibrinogen disorders and genotype/phenotype correlations. Blood Transfus. 2019; 17(3): 247–54. DOI: 10.2450/2018.0123-18.

31. Lounes K.C., Soria C., Mirshahi S.S., et al. Fibrinogen Ale`s: A homozygous case of dysfibrinogenemia (g-Asp3303Val) characterized by a defective fibrin polymerization site “a”. Blood. 2000; 96(10): 3473–9.

32. Reber P., Furlan M., Henschen A., et al. Three abnormal fibrinogen variants with the same amino acid substitution (gamma 275 Arg----His): Fibrinogens Bergamo II, Essen and Perugia. Thromb Haemost. 1986; 56(3): 401–6.

33. Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med. 2002; 126(11): 1387–90. DOI: 10.5858/2002-126-1387-DAT.

34. Krammer B., Anders O., Nagel H.R., et al. Screening of dysfibrinogenaemia using the fibrinogen function versus antigen concentration ratio. Thromb Res. 1994; 76(6): 577–9. DOI: 10.1016/0049-3848(94)90287-9.

35. Cunningham M.T., Brandt J.T., Laposata M., Olson J.D. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med. 2002; 126(4): 499–505. DOI: 10.5858/2002-126-0499-LDOD.